LINE

Text:AAAPrint
Economy

China fines domestic medicine companies for monopoly pricing

1
2017-07-31 16:27Xinhua Editor: Mo Hong'e ECNS App Download

China's top economic planner announced Monday that two domestic medicine firms had been fined for monopoly pricing practices.

Zhejiang Second Pharma and Tianjin Handewei Pharmaceutical were fined a total of 443,900 yuan (65,975 U.S. dollars) for fixing prices for an active pharmaceutical ingredient, said a National Development and Reform Commission (NDRC) statement.

The two companies charged an unfairly high price for Isoniazid, an antibiotic used to treat tuberculosis, and declined sales with no justified cause, the statement said.

The two companies have since restored regular pricing and revived market competition.

Monopoly practices in the pharmaceutical sector have been a focus of China's anti-monopoly supervision for some time. The case will help regulate active pharmaceutical ingredient pricing and ensure a fair environment for medicine purchases and sales, according to the NDRC.

The NDRC has vowed to increase anti-monopoly supervision to protect market order, consumers and businesses.

  

Related news

MorePhoto

Most popular in 24h

MoreTop news

MoreVideo

News
Politics
Business
Society
Culture
Military
Sci-tech
Entertainment
Sports
Odd
Features
Biz
Economy
Travel
Travel News
Travel Types
Events
Food
Hotel
Bar & Club
Architecture
Gallery
Photo
CNS Photo
Video
Video
Learning Chinese
Learn About China
Social Chinese
Business Chinese
Buzz Words
Bilingual
Resources
ECNS Wire
Special Coverage
Infographics
Voices
LINE
Back to top Links | About Us | Jobs | Contact Us | Privacy Policy
Copyright ©1999-2018 Chinanews.com. All rights reserved.
Reproduction in whole or in part without permission is prohibited.